Bayer AG (XSWX:BAYN) Total Equity: CHF26,360 Mil (As of Mar. 2026)


XSWX:BAYN Bayer AG XSWX:BAYN
54 GF Score
Price CHF42.49
GF Value CHF24.74
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG Total Equity?

Bayer AG XSWX:BAYN 54 Total Equity is CHF26,360 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 54/100 and a GF Value™ of CHF24.74 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Bayer AG's total equity for the quarter that ended in Mar. 2026 was CHF26,360 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bayer AG Total Equity Historical Data

* Premium members only.

The historical data trend for Bayer AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Total Equity Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34,517.21 38,414.68 31,195.04 29,917.62 24,320.38

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31,123.74 28,607.38 27,752.31 24,320.38 26,360.44
XSWX:BAYN
54GF Score
Bayer AG XSWX:BAYN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bayer AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=97551.198-73230.818
=24,320

Bayer AG's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=98247.759-71887.316
=26,360

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of CHF26,360 Mil mean?
Bayer AG (XSWX:BAYN) has a Total Equity of CHF26,360 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Bayer AG and its competitors.
Is Bayer AG's Total Equity too high?
Bayer AG's current Total Equity is CHF26,360 Mil. Overall, Bayer AG has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Total Equity compare to LLY and JNJ?
Bayer AG's Total Equity of CHF26,360 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Bayer AG and its competitors. Bayer AG's current Total Equity is CHF26,360 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.74, compared to a current price of CHF42.49 — trading 71.7% above its estimated fair value. The current Total Equity is CHF26,360 Mil. Bayer AG's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Total Equity is CHF26,360 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF42.49 is trading 71.7% above its estimated GF Value™ of CHF24.74. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Total Equity: CHF26,360 Mil
  • GF Value™: CHF24.74 vs. price of CHF42.49 (71.7% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
54GF Score

Get the complete analysis for XSWX:BAYN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF42.49
Price
CHF24.74
GF Value